Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) CEO Sells $5,838,864.60 in Stock

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) CEO David E. Lazar sold 194,628,820 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total transaction of $5,838,864.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Cyclacel Pharmaceuticals Price Performance

Shares of NASDAQ CYCC opened at $0.33 on Friday. The company has a 50 day simple moving average of $0.36 and a 200-day simple moving average of $0.65. The company has a market capitalization of $2.08 million, a P/E ratio of -0.04 and a beta of 0.35. Cyclacel Pharmaceuticals, Inc. has a 1 year low of $0.30 and a 1 year high of $4.00.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals in a report on Thursday. They set a “sell” rating for the company.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.